Critical Survey: Allarity Therapeutics (NASDAQ:ALLR) and Emerald Health Therapeutics (OTCMKTS:EMHTF)

Allarity Therapeutics (NASDAQ:ALLR) and Emerald Health Therapeutics (OTCMKTS:EMHTF) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Profitability

This table compares Allarity Therapeutics and Emerald Health Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
Emerald Health Therapeutics	N/A	N/A	N/A

Institutional & Insider Ownership

11.5% of Allarity Therapeutics shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Allarity Therapeutics and Emerald Health Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320,000.00	69.61	-$11.23 million	($0.72)	-1.94
Emerald Health Therapeutics	N/A	N/A	N/A	N/A	N/A

Emerald Health Therapeutics has lower revenue, but higher earnings than Allarity Therapeutics.

Analyst Ratings

This is a breakdown of recent ratings for Allarity Therapeutics and Emerald Health Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1	0	1	0	2.00
Emerald Health Therapeutics	0	0	0	0	0.00

Allarity Therapeutics presently has a consensus price target of $10.25, indicating a potential upside of 632.14%. Given Allarity Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Allarity Therapeutics is more favorable than Emerald Health Therapeutics.

Summary

Allarity Therapeutics beats Emerald Health Therapeutics on 6 of the 8 factors compared between the two stocks.

About Allarity Therapeutics

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

About Emerald Health Therapeutics

Emerald Health Therapeutics, Inc., together with its subsidiaries, engages in the production, distribution, and sale of recreational and medical cannabis in Canada. It offers dried cannabis strains, pre-rolled cannabis, oral sprays, nano emulsion shots, and cannabis oil products under the SYNC Wellness, fuse, Emerald, and Souvenir brands. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.